EPIPHANY Index for PE in Cancer
Predicts clinical outcome of pulmonary embolism (PE) in cancer patients. Guides management intensity (outpatient vs admission vs ICU) and anticoagulation decisions.
Score interpretation
→ EPIPHANY High Risk (≥3): High mortality risk PE in cancer. ICU/HDU admission; full anticoagulation (LMWH preferred in cancer — dalteparin or DOAC if low bleeding risk per CARAVAGGIO trial); consider systemic thrombolysis if massive PE; haematology/oncology involvement.
→ EPIPHANY Intermediate Risk (1–2): Moderate mortality risk. Hospital admission; LMWH (therapeutic dose dalteparin/tinzaparin) or DOAC (apixaban, rivaroxaban); monitor for deterioration; oncology review.
→ EPIPHANY Low Risk (0): Low mortality risk. Consider outpatient management if ECOG 0–1, haemodynamically stable, and social support adequate; DOAC preferred (apixaban or rivaroxaban); oncology follow-up within 48 hours.
Interpretation bands for the EPIPHANY Index. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Sildenafil · PDE5 Inhibitor — Pulmonary Arterial Hypertension
- Dalteparin · Low Molecular Weight Heparin — VTE Treatment / Cancer-Associated Thrombosis
- Nitric Oxide (Inhaled — iNO) · Selective Pulmonary Vasodilator
- Enoxaparin (LMWH) · Anticoagulant
- Selexipag · Pulmonary Arterial Hypertension
- Macitentan · Pulmonary Arterial Hypertension
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- Acute Exacerbation of COPD (AECOPD) · NICE NG115; GOLD 2024
- Spontaneous Pneumothorax (Adult) · BTS Pleural Disease 2023
- Atypical Pneumonia (Legionella / Mycoplasma / Chlamydophila) · BTS 2023; IDSA
- COPD Exacerbation Management · NICE NG115 / GOLD 2024
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.